Toxina botulínica A para o trismo no tétano cefálico

Cephalic tetanus is a localized form of tetanus. As in generalized forms , trismus is a prominent feature of the disease, leading to considerable difficulty in feeding, swallowing of the saliva and mouth hygiene. These difficulties often precede respiratory problems and aspiration bronchopneumonia is a frequent life-threatening complication. Muscle relaxants other than curare drugs may show a limited benefit for relieving trismus. Tetanospasmin, the tetanic neurotoxin, and botulinum toxin share many similarities, having a closely related chemical structure, an origin from related microorganisms (Clostridium tetani and Clostridium botulinum, respectively), and presumably, the same mechanisms of action in the neuron. The difference between the two lies in their peculiar neurospecificity, acting in different neurons. Injection of minute doses of botulinum toxin in the muscles involved in focal dystonias or other localized spastic disorders have proved to be very effective in these conditions. We describe the use of botulinum toxin A in the successful treatment of trismus in a patient suffering from cephalic tetanus. We believe that this form of treatment may be of value in lowering the risk of pulmonary complications in tetanic patients.O tétano cefálico é uma forma localizada de tétano. Da mesma maneira que nas formas generalizadas, o trismo é componente clínico proeminente, que leva a grande dificuldade na alimentação, na deglutição da saliva e para a higiene da boca. Essas dificuldades freqüentemente precedem os problemas respiratórios e as pneumonias aspirativas, que se constituem em complicações que ameaçam a vida dos pacientes. Drogas relaxantes musculares de outro tipo que as drogas curarizantes trazem pouco benefício para o trismo. A neurotoxina tetânica (tetanospasmin) e a toxina botulínica compartilham muitas semelhanças, como estrutura química símile, origem de microorganismos relacionados (Clostridium tetani e Clostridium botulinum, respectivamente) e, presumivelmente, os mesmos mecanismos de ação no neurônio. A diferença entre as duas reside na sua peculiar neuroespecificidade, atuando em diferentes neurônios. Injeção de doses reduzidas da toxina botulínica em músculos envolvidos em distonias focais ou outras desordens com espasticidade muscular localizada tem se mostrado eficaz em abolir as contrações. Descrevemos o uso da toxina botulínica A com sucesso no tratamento do trismo num paciente sofrendo de tétano cefálico. Acreditamos que esta forma de tratamento possa ser de valor no sentido de diminuir o risco de complicações pulmonares nos pacientes com tétano.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Escola Paulista de Medicina Department of Neurology and NeurosurgeryUNIFESP, EPM, Department of Neurology and NeurosurgerySciEL

Advancements in dementia research, diagnostics and care in Latin America : highlights from the 2023 Alzheimer's association international conference satellite symposium in Mexico City

While Latin America (LatAm) is facing an increasing burden of dementia due to the rapid aging of the population, it remains underrepresented in dementia research, diagnostics and care. In 2023, the Alzheimer’s Association hosted its eighth Satellite Symposium in Mexico, highlighting emerging dementia research, priorities, and challenges within LatAm. A wide range of topics were covered, including epidemiology, social determinants, dementia national plans, risk reduction, genetics, biomarkers, biobanks, and advancements in treatments. Large initiatives in the region including intra-country support showcased their efforts in fostering national and international collaborations; genetic studies unveiled the unique genetic admixture in LatAm; emerging clinical trials discussed ongoing culturally specific interventions; and the urgent need to harmonize practices and studies, improve diagnosis and care and implement affordable biomarkers in the region was highlighted

Phonemic verbal fluency and age: A preliminary study

Abstract Verbal fluency (VF) has been one of the most frequently used instruments in clinics and research, both independently or included in a battery recommended for the detection of cognitive alterations. Phonemic-verbal fluency (PVF) is an interesting variant for cognitive diagnosis particularly because studies indicate that it is less influenced by age. Objectives: 1. To estimate the effects of age on PVF tests in their original forms, with the /f/-/a/-/s/ phonemes. 2. To estimate the effects of the phoneme /p/ and compare it to the original form in item generation. 3. To verify associations between the Token Test (TT), Mini-Mental State Exam (MMSE) and depressive symptoms on performance with /f/-/a/-/s/-/p/ phonemes. Methods: Forty-eight healthy individuals with ages ranging from 30 to 80 years were evaluated with the MMSE, TT and PVF tests. Results: Age was correlated with the MMSE, TT and depressive symptoms. There was no association between age and performance on the fluency test, independent of the phoneme used. Among the socio-demographic factors studied, age had a significant impact on performance. There was no phoneme effect in item-generation, when comparing the traditional form of VF (/f/-/a/-/s/) and the /p/ phoneme. Conclusions: The traditional form of FAS is interchangeable with the modified presentation, therefore both forms may be used in clinical or research settings. PVF is a valuable approach for detecting cognitive alterations in the aged, given its stability throughout the ageing process

Impact of stroke unit in a public hospital on length of hospitalization and rate of early mortality of ischemic stroke patients

We ascertained whether a public health stroke unit reduces the length of hospitalization, the rate of inpatient fatality, and the mortality rate 30 days after the stroke. Methods We compared a cohort of stroke patients managed on a general neurology/medical ward with a similar cohort of stroke patients managed in a str oke unit. The in-patient fatality rates and 30-day mortality rates were analyzed. Results 729 patients were managed in the general ward and 344 were treated at a comprehensive stroke unit. The in-patient fatality rates were 14.7% for the general ward group and 6.9% for the stroke unit group (p<0.001). The overall mortality rate 30 days after stroke was 20.9% for general ward patients and 14.2% for stroke unit patients (p=0.005). Conclusions We observed reduced in-patient fatalities and 30-day mortality rates in patients managed in the stroke unit. There was no impact on the length of hospitalization

Dementia in Parkinson's disease: a Brazilian sample

To determine the prevalence of dementia associated with Parkinson's disease (PD-D) in a Brazilian sample adopting clinical and diagnostic procedures recommended by the Movement Disorders Society (MDS). Sixty-seven patients were consecutively submitted to neurological, neuropsychological and functional examinations. PD-D was established according to MDS clinical criteria (Level II) and clinical procedures for PD-D (Level I) and prevalence rate was compared between the levels adopted. Ten patients (14.9%) were diagnosed as demented by Level I criteria whereas sixteen (23.8%) were diagnosed based on Level II criteria. Level I criteria had low sensitivity in detecting PD-D (31.25%), but greater specificity (90.19). The PD-D group had significantly worse performance on all neuropsychological tests, were older (p<0.001), had an older age of onset ofdisease (p<0.01), had lower educational level (p<0.02) and had higher scores on functional scales. Current age (p=0.046) and Hoehn & Yahr score (p=0.048) were predictors for developing PD-D